US · Healthcare · Biotechnology
EPS came in at -0.05 against a street estimate of -0.04 — a miss of 25.0%.
Analysts rate Sellas Life Sciences Group Inc a strong buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $32.50.
| Fund | Stake |
|---|---|
| BlackRock Inc | 6.04% |
| State Street Corp | 4.16% |
| Vanguard Capital Management, LLC | 3.73% |
| Geode Capital Management, LLC | 1.94% |
| Marshall Wace Asset Management Ltd | 1.01% |
| JONES FINANCIAL COMPANIES LLLP | 0.83% |
| Vanguard Portfolio Management, LLC | 0.72% |
| Morgan Stanley - Brokerage Accounts | 0.66% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 SELLAS LIFE SCIENCES GROUP, INC. – Q2 2026 SUMMARY --- HEADLINE NUMBERS • Cash position: $138.3 million as of June 30, 2026 (up from $71.8 million | 2026-08-11 |
| Results announced · Q3 2026 SELLAS LIFE SCIENCES GROUP, INC. — Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Cash position: $138.3 million in cash and cash equivalents as of Jun | 2026-08-11 |
| Results announced · Q3 2026 SELLAS LIFE SCIENCES GROUP, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Cash and cash equivalents position as of June 30, 2026: $138.3 million (unaud | 2026-07-27 |
| Board / officer change · Q2 2026 SELLAS LIFE SCIENCES GROUP, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • No financial performance metrics disclosed in this filing • Document dated Ju | 2026-06-25 |
| Shareholder vote results · Q2 2026 SELLAS LIFE SCIENCES GROUP, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting of Stockholders held June 16, 2026 • 115,511,771 shares presen | 2026-06-18 |
| Quarterly report · Q1 2026 SELLAS LIFE SCIENCES GROUP, INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash position: $107.1 million as of March 31, 2026 (up from $71.8 million | 2026-05-12 |
| Proxy statement · Q2 2026 SELLAS LIFE SCIENCES GROUP, INC. — PROXY STATEMENT SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect two (2) Class I directors for three-y | 2026-04-23 |
| Annual report FY2025 SELLAS LIFE SCIENCES GROUP, INC. – FORM 10-K SUMMARY HEADLINE NUMBERS • Company is a late-stage clinical biopharmaceutical firm focused on cancer th | 2026-03-19 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Sellas Life Sciences Group Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.